PDCD1 and melanoma: ACT using Pmel or CD38 knockout Pmel (Pmel-CD38−/−) T cells either alone or in combination with anti-PD1 therapy (Fig. 4C) delayed tumor progression in mice bearing B16-F10 mouse melanoma tumor as compared to mice without ACT (control) (Fig. 4 D and E).